The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
The FDA has expanded the approval of a new option for the treatment of adults and children aged 12 years or older or weighing at least 99 pounds with chronic hepatitis C virus genotypes 1, 2, 3, 4, 5, or 6...
The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.
